Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when NVAX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsNovavax Q1 revenue falls 79% to $140M; signs Matrix-M deals with Pfizer, others
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 revenue of $140M, down 79% year-over-year, primarily due to prior-year $603M non-cash revenue from closed advance purchase agreements. Licensing revenue of $97M included $30M from Pfizer Matrix-M deal.
Exhibit 99.1 view on EDGAR → -
high
Pfizer Matrix-M license signed January 2026 for two infectious disease areas: $30M upfront (received Q1), up to $500M in milestones, and high-mid-single digit royalties on product sales.
Exhibit 99.1 view on EDGAR → -
high
Four new or expanded Matrix-M material transfer agreements signed in Q1 2026, including with a top-ten pharma for oncology and infectious disease targets. Company now has agreements with four of top ten global pharmas covering 30+ fields.
Exhibit 99.1 view on EDGAR → -
medium
C. difficile vaccine candidate prioritized as next potential clinical asset, targeting clinic entry as early as 2027.
Exhibit 99.1 view on EDGAR → -
medium
2026 non-GAAP R&D and SG&A expense guidance of $325M (midpoint), 2027 guidance of $225M, and improved 2028 target of $150-200M, representing over 50% reduction versus 2025.
Exhibit 99.1 view on EDGAR →
Summary
Novavax reported Q1 2026 results showing the company's strategic pivot from COVID-19 vaccine sales to a technology licensing model. Revenue of $140 million fell 79% year-over-year, but the decline reflects the prior-year period's $603 million in non-cash revenue from closing out advance purchase agreements rather than operational deterioration. The quarter's $97 million in licensing revenue, including $30 million from the Pfizer Matrix-M deal, demonstrates early traction for the adjuvant technology platform.
The Pfizer agreement, signed in January 2026, grants non-exclusive rights to Matrix-M for two infectious disease areas with potential for up to $500 million in milestones plus royalties. Novavax expanded its partnership footprint with four new or expanded material transfer agreements in Q1, now working with four of the world's ten largest pharmaceutical companies across more than 30 disease areas spanning infectious diseases and oncology. The company is advancing its internal pipeline by prioritizing the C. difficile vaccine for potential 2027 clinical entry while targeting significant expense reductions: $325 million in 2026, $225 million in 2027, and $150-200 million by 2028, representing over 50% reduction from 2025 levels.
Section-by-Section Diff
Event · Exhibit 99.1
Novavax reported Q1 2026 revenue of $140M, signed Matrix-M licensing deals with Pfizer and others, and prioritized C. difficile vaccine for 2027 clinic entry.
Added in current filing · view on EDGAR → · paraphrased
In April, Novavax signed a new material transfer agreement (MTA) with a top ten global pharmaceutical company who is also a global leader in oncology to explore Matrix-M in a broad array of oncology targets, as well as antibiotic resistant bacterial infections and other infectious diseases. In April, Novavax signed a new MTA with an existing pharmaceutical partner for evaluation of Matrix-M in nine additional, identified disease areas. In February, Novavax expanded an existing MTA with a major global pharmaceutical company to explore an additional field and signed a new MTA with an innovative oncology company.
Novavax signed four new or expanded MTAs in Q1 2026, including agreements with a top-ten pharma company for oncology and infectious disease targets, an existing partner for nine additional disease areas, and two other companies. The company now has MTA or license agreements with four of the top ten global pharma companies covering over 30 unique fields of experimentation across infectious diseases and oncology.
Added in current filing · view on EDGAR →
Clostridioides difficile colitis (C. difficile) vaccine candidate prioritized as potential next asset to enter the clinic as early as 2027.
Novavax prioritized its C. difficile vaccine candidate as the next potential asset to advance to clinical trials, with entry into the clinic targeted for as early as 2027. This represents the company's internal R&D pipeline advancement alongside its technology partnering strategy.
Added in current filing · view on EDGAR →
Targeting full year Non-GAAP combined R&D and Selling, General and Administrative (SG&A) expenses of $325 million for full year 2026 and $225 million for full year 2027, each period at the midpoint of the guidance range. ... Improving the 2028 target for full year Non-GAAP combined R&D and SG&A expenses to between $150 million and $200 million. This reflects an anticipated expense reduction of over $200 million and over 50% when compared to full year 2025.
Novavax reiterated its 2026 non-GAAP combined R&D and SG&A expense guidance of $310-340 million (midpoint $325 million) and provided 2027 guidance of $225 million at the midpoint. The company improved its 2028 target to $150-200 million, representing over $200 million and over 50% reduction versus full year 2025 as part of its ongoing cost reduction program.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 25, 2026 · How we verify